IceCure Medical (ICCM) Registration Filing summary

Company overview and business model

• Commercial-stage medical device company specializing in cryoablation systems using liquid nitrogen for tumor treatment, offering minimally invasive alternatives to surgery for various tumor types, with ProSense as the lead product.

• Principal operations and R&D are based in Israel, with global subsidiaries and a Nasdaq listing.

Financial performance and metrics

• As of March 31, 2025, cash and cash equivalents were $6.0 million, with an accumulated deficit of $109.0 million.

• The net tangible book value per share as of March 31, 2025, was $0.10, with an immediate dilution of $0.78 per share for new investors in the offering.

Use of proceeds and capital allocation

• Net proceeds of approximately $9.3 million (if fully subscribed) will be used to repay a $2 million bridge loan and for general corporate and working capital purposes.

• Management retains broad discretion over allocation of net proceeds.